1621999-82-3 Usage
Description
(N-(2-((2-((2-methoxy-5-methylpyridin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-5-methylphenyl)acrylamide) is a complex organic compound belonging to the acrylamide family. It features a molecular formula of C21H20F3N5O2 and is characterized by the presence of a trifluoromethyl group, a pyrimidinylamino group, a pyridinylamino group, a methoxy group, and a phenyl ring. Its intricate structure and multiple functional groups suggest potential applications in research and pharmaceutical development due to its resemblance to biologically active compounds.
Used in Pharmaceutical Development:
(N-(2-((2-((2-methoxy-5-methylpyridin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-5-methylphenyl)acrylamide) is used as a research reagent for the development of pharmaceutical drugs. Its complex structure and functional groups make it a promising candidate for the creation of new therapeutic agents.
Used in Chemical Research:
In the field of chemical research, (N-(2-((2-((2-methoxy-5-methylpyridin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-5-methylphenyl)acrylamide) serves as a valuable compound for studying the properties and reactions of complex organic molecules. Its unique structure allows researchers to explore various chemical interactions and potential applications in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1621999-82-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,1,9,9 and 9 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1621999-82:
(9*1)+(8*6)+(7*2)+(6*1)+(5*9)+(4*9)+(3*9)+(2*8)+(1*2)=203
203 % 10 = 3
So 1621999-82-3 is a valid CAS Registry Number.
1621999-82-3Relevant articles and documents
HETEROARYL COMPOUNDS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
-
Paragraph 00353-00356, (2016/12/07)
The present invention relates to methods for synthesizing compounds useful as inhibitors or both of ERK1 and ERK2 kinase, derivatives thereof, and intermediates thereto.
METHODS OF TREATMENT USING AN ERK INHIBITOR
-
, (2016/02/29)
The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with one or both of ERK1 and ERK2.
COMBINATIONS OF AN ERK INHIBITOR AND A RAF INHIBITOR AND RELATED METHODS
-
Paragraph 00136, (2016/02/29)
The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with one or both of ERK1 and ERK2.
